These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm. Chau AS; Weber AG; Maria NI; Narain S; Liu A; Hajizadeh N; Malhotra P; Bloom O; Marder G; Kaplan B Arthritis Rheumatol; 2021 Jan; 73(1):23-35. PubMed ID: 32929876 [TBL] [Abstract][Full Text] [Related]
43. Corticosteroids in SARS-COV2 infection: certainties and uncertainties in clinical practice. Crisan Dabija R; Antohe I; Trofor A; Antoniu SA Expert Rev Anti Infect Ther; 2021 Dec; 19(12):1553-1562. PubMed ID: 34015985 [TBL] [Abstract][Full Text] [Related]
44. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy. Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027 [TBL] [Abstract][Full Text] [Related]
45. The understanding of the immunopathology in COVID-19 infection. Tascioglu D; Akkaya E; Genc S Scand J Clin Lab Invest; 2021 Jul; 81(4):255-263. PubMed ID: 34032527 [TBL] [Abstract][Full Text] [Related]
46. Corticosteroids for COVID-19 patients requiring oxygen support? Yes, but not for everyone: Effect of corticosteroids on mortality and intensive care unit admission in patients with COVID-19 according to patients' oxygen requirements. Tortajada C; Colomer E; Andreu-Ballester JC; Esparcia A; Oltra C; Flores J J Med Virol; 2021 Mar; 93(3):1817-1823. PubMed ID: 33107607 [TBL] [Abstract][Full Text] [Related]
47. Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection. Bahari Z; Jangravi Z; Ghoshooni H; Afarinesh MR; Meftahi GH Inflamm Res; 2021 Apr; 70(4):389-405. PubMed ID: 33608746 [TBL] [Abstract][Full Text] [Related]
48. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast. Almerie MQ; Kerrigan DD Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562 [TBL] [Abstract][Full Text] [Related]
49. Pathogenic role of cytokines in COVID-19, its association with contributing co-morbidities and possible therapeutic regimens. Tanveer A; Akhtar B; Sharif A; Saleem U; Rasul A; Ahmad A; Jilani K Inflammopharmacology; 2022 Oct; 30(5):1503-1516. PubMed ID: 35948809 [TBL] [Abstract][Full Text] [Related]
50. COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied? Macciò A; Oppi S; Madeddu C J Ovarian Res; 2021 Feb; 14(1):28. PubMed ID: 33550983 [TBL] [Abstract][Full Text] [Related]
51. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19. Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158 [TBL] [Abstract][Full Text] [Related]
53. Interaction of Vitamin D and Corticosteroid Use in Hospitalized COVID-19 Patients: A Potential Explanation for Inconsistent Findings in the Literature. Efird JT; Anderson EJ; Jindal C; Suzuki A Curr Pharm Des; 2022; 28(21):1695-1702. PubMed ID: 35440302 [TBL] [Abstract][Full Text] [Related]
54. Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation. Janssen MTHF; Ramiro S; Landewé RBM; Magro-Checa C; Mostard RLM Ann Rheum Dis; 2021 Oct; 80(10):1362-1363. PubMed ID: 33958327 [No Abstract] [Full Text] [Related]
55. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. Liu J; Zhang S; Dong X; Li Z; Xu Q; Feng H; Cai J; Huang S; Guo J; Zhang L; Chen Y; Zhu W; Du H; Liu Y; Wang T; Chen L; Wen Z; Annane D; Qu J; Chen D J Clin Invest; 2020 Dec; 130(12):6417-6428. PubMed ID: 33141117 [TBL] [Abstract][Full Text] [Related]
57. Phytotherapy for treatment of cytokine storm in COVID-19. Sapra L; Bhardwaj A; Azam Z; Madhry D; Verma B; Rathore S; Srivastava RK Front Biosci (Landmark Ed); 2021 Apr; 26(5):51-75. PubMed ID: 34027650 [TBL] [Abstract][Full Text] [Related]
58. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone. Olajide OA; Iwuanyanwu VU; Lepiarz-Raba I; Al-Hindawi AA Inflammation; 2021 Oct; 44(5):1865-1877. PubMed ID: 33860869 [TBL] [Abstract][Full Text] [Related]
59. Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome. Perlin DS; Neil GA; Anderson C; Zafir-Lavie I; Raines S; Ware CF; Wilkins HJ J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 34871182 [TBL] [Abstract][Full Text] [Related]
60. COVID-19 and influenza A coinfection: a matter of principle. Lozano-Parras MA; Amann-Arévalo M; Ciller-Martínez M; Culebras-López E Enferm Infecc Microbiol Clin (Engl Ed); 2021 Apr; 39(4):214-215. PubMed ID: 32782078 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]